Project Grant R21AI182544
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$445K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This $736,920 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to determine the atomic-level structure, assembly, and function of the flagellum in the protozoan parasite Trypanosoma brucei. T. brucei causes African trypanosomiasis, also known as sleeping sickness, a fatal disease for which no vaccine exists. The research aims to leverage advanced cryo-electron...
This $449,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) aims to develop antibody-based diagnostic tools for Chagas disease. The project, led by Duke University, will generate a panel of antibodies that can detect markers of Trypanosoma cruzi infection in blood samples from dogs, non-human primates, and humans. The successful completion of this 2-year effort is...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $431,004 to the University of California, Davis to investigate the fundamental mechanisms underlying the process of "trogocytosis" between the pathogenic amoeba Entamoeba histolytica and human cells. The research aims to elucidate the dynamic interplay between the amoeba and human cells during this...
The University of Texas Medical Branch at Galveston (UTMB) was awarded a $440,000 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant, awarded on July 3, 2025 with a completion date of June 30, 2027, will support research to determine the function and mechanism of the long non-coding RNA CHAST in Trypanosoma cruzi infection and dissemination, which causes Chagas...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $812,603 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to the University of Houston System. The grant aims to develop selective calcium-dependent protein kinase 1 (CDPK1) inhibitors that can efficiently access the gastrointestinal system to treat cryptosporidiosis, a significant public health threat with limited treatment options. The research will focus on structure-activity...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $689,068 Project Grant under CFDA 93.855 Allergy and Infectious Diseases Research to the University of Cincinnati to establish ex vivo growth systems for the fungal genus Pneumocystis. The key objectives are to: 1) conduct metabolite profiling and flux balance analysis to identify critical nutrients for growth of the P. carinii surrogate in a cell-free culture system, and 2) develop rat and human alveolar organoids to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $504,703 to the University of Georgia Research Foundation (UGA Research Foundation) to optimize and fully integrate an "UltraPCR" diagnostic platform for improved detection and assessment of treatment outcomes for Trypanosoma cruzi infection, the causative agent of Chagas disease. The overarching goal...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $408,865 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Vermont & State Agricultural College. The grant supports the development of new tools to study how the protozoan parasite Toxoplasma gondii delivers its "rhoptry effector" proteins into host cells during the invasion process. The goals are to: 1) Develop an assay to test whether the rhoptry...
This Project Grant award of $1,283,899.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), supports research to investigate treatment outcomes and disease prevention strategies for Chagas disease. The primary awardee, the University of Georgia Research Foundation, Inc., will conduct studies in a natural setting of high-intensity Trypanosoma cruzi infection in working dogs in South...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), supports a $453,429 research project on the "Regulation of RNA Editing in Two Life Cycle Stages of Trypanosoma brucei". The 5-year project aims to investigate the key proteins and mechanisms involved in differential RNA editing across the life cycle of this pathogenic kinetoplastid protozoan, which alternates between mammalian...